-
Research Progress of NK Cells in Glioblastoma Treatment
17 Jan 2025 13:59 GMT
… undergoing clinical trials for GBM treatment (CAR2BRAIN; NCT0338978 … continuous progress of biotechnology, we firmly believe … Doctor Foundation of the Second Affiliated Hospital of Xi’an Medical … histone deacetylase inhibitor trichostatin a promotes apoptosis …
-
The Advances in the Development of Epigenetic Modifications Therapeutic Drugs Delivery Systems
18 Oct 2024 12:49 GMT
… effectiveness of epigenetic medications. By improving permeability … trials were isohydroxamic acid analogs.69 The FDA-approved drug … belinostat [PXD101], and trichostatin A [TSA]) were … trial data for nano-based epigenetic drugs in breast cancer treatment …
-
Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VTR-297 a Topical Antifungal Candidate for the Treatment of Onychomycosis
31 Jan 2024 17:12 GMT
… . Onychomycosis: a significant medical disorder. J Am Acad … A New Antifungal Antibiotic, Trichostatin. J Antibiot (Tokyo). … VTR-297 in the treatment of onychomycosis. Therefore, … -pharmaceuticals-receives-fda-approval-to-proceed-with-investigational-new-drug …
-
HDAC Inhibitor Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
08 Jan 2024 18:00 GMT
… HDAC inhibitor drugs to improve the treatment landscape. … acids (e.g., trichostatin A, vorinostat), cyclic … Tracon Pharmaceuticals Inc., Celgene, MedImmune, Hangzhou Sumgen Biotech, Lepu … , Jiangsu Hengrui Medicine Co., MaxiNovel Pharmaceuticals, among others …
-
HRT Financial LP Has $396,000 Position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)
06 Jun 2023 10:25 GMT
… of therapies for high unmet medical needs. The firm intends to … portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051.
Featured Stories
Want … analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat …
-
Vanda Pharmaceuticals (NASDAQ:VNDA) Downgraded by StockNews.com to “Buy”
02 Jun 2023 07:52 GMT
… institutional investors.
About Vanda Pharmaceuticals
(Get Rating)
Vanda Pharmaceuticals, Inc engages in … of therapies for high unmet medical needs. The firm intends to … , Trichostatin, and AQW051.
See Also
Receive News & Ratings for Vanda Pharmaceuticals …
-
Fisher Asset Management LLC Boosts Holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)
29 Apr 2023 12:15 GMT
… company insiders.
About Vanda Pharmaceuticals
(Get Rating)
Vanda Pharmaceuticals, Inc engages in … of therapies for high unmet medical needs. The firm intends to … , Trichostatin, and AQW051.
See Also
Receive News & Ratings for Vanda Pharmaceuticals …
-
Potential Treatment Strategies for Hepatocellular Carcinoma Cell Sensitization to Sorafenib
16 Feb 2023 01:14 GMT
… multi-center, prospective clinical trial (NCT01217034) compared the efficacy … to support further clinical trials.
Natural Compounds and … with sorafenib combined with trichostatin A. Oncol Lett. … in the treatment of hepatocellular carcinoma? Medicine. 2020;99 …
-
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Shares Bought by Victory Capital Management Inc.
01 Feb 2023 13:14 GMT
… November 11th.
Vanda Pharmaceuticals Profile
(Get Rating)
Vanda Pharmaceuticals, Inc engages in … of therapies for high unmet medical needs. The firm intends to … portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051.
Featured Articles
Want …
-
Integrated platform promises to accelerate drug discovery process
01 Dec 2022 11:44 GMT
… products to identify potential drugs remains a difficult undertaking … University of Texas Southwestern Medical Center.
By integrating the … identify a known compound (trichostatin A) and confirm its … platform promises to accelerate drug discovery process (2022, …
About
© 1995-2025